x

¿Aún no está registrado?

Cree su cuenta. Regístrese en Elsevier y obtendrá: información relevante, máxima actualización y promociones exclusivas.

Registrarme ahora
Ayuda - - Regístrese - Teléfono 902 888 740
Buscar en

FI 2015

1,267
© Thomson Reuters, Journal Citation Reports, 2015

Indexada en:

Current Contents/Clinical Medicine, Journal Citation Reports, SCI-Expanded, Index Medicus/Medline, Excerpta Medica/EMBASE, IBECS, IME, MEDES, PASCAL, SCOPUS, ScienceDirect

Métricas

  • Factor de Impacto: 1,267(2015)
  • 5-años Factor de Impacto: 1,344
  • SCImago Journal Rank (SJR):0,221
  • Source Normalized Impact per Paper (SNIP):0,385
Med Clin 2000;115:392-7 - DOI: 10.1016/S0025-7753(00)71569-7
PPARγ y tiazolidinedionas, algo más que un tratamiento contra la diabetes
Gema Medinaa,b, Ciaran Sewtera, Antonio J Vidal Puiga,,
a Department of Medicine and Clinical Biochemistry. Addenbrooke's Hospital. University of Cambridge.
b Instituto de Investigaciones Biomédicas Alberto Sols. CSIC. Universidad Autónoma de Madrid.
Recibido 17 mayo 2000, Aceptado 30 junio 2000
El Texto completo solo está disponible en PDF
Referencias bibliográficas
1.
J.M. Lehmann,L.B. Moore,T.A. Smith-Oliver,W.O. Wilkison,T.M. Willson,S.A. Kliewer
An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor gamma (PPAR gamma)
J Biol Chem, 12953 (1995), pp. 12956
2.
s. Rocchi,J. Auwerx
Peroxisome proliferator-activated receptor-gamma: a versatile metabolic regulator
Ann Med, 31 (1999), pp. 342-351
3.
R. Komers,A. Vrana
Thiazolidinediones-tools for the research of metabolic syndrome X
Physiol Res, 47 (1998), pp. 215-225
4.
C. Day
Thiazolidinediones: a new class of antidiabetic drugs
Diabet Med, 16 (1999), pp. 179-192
5.
L. Gelman,J.C. Fruchart,J. Auwerx
An update on the mechanisms of action of the peroxisome proliferator- activated receptors (PPARs) and their roles in inflammation and cancer
Cell Mol Life Sci, 55 (1999), pp. 932-943
6.
T.M. Willson,P.J. Brown,D.D. Sternbach,B.R. Henke
The PPARs: from orphan receptors to drug discovery
J Med Chem, 43 (2000), pp. 527-550
7.
I. Pineda Torra,P. Gervois,B. Staels
Peroxisome proliferator-activated receptor alpha in metabolic disease, inflammation, atherosclerosis and aging
Curr Opin Lipidol, 10 (1999), pp. 151-159
8.
P. Sarraf,E. Mueller,D. Jones,F.J. King,D.J. DeAngelo,J.B. Partridge
Differentiation and reversal of malignant changes in colon cancer through PPARgamma
Nat Med, 4 (1998), pp. 1046-1052
9.
H.F. Tabak,I. Braakman,B. Distel
Peroxisomes: simple in function but complex in maintenance
Trends Cell Biol, 9 (1999), pp. 447-453
10.
J. Vamecq,N. Latruffe
Medical significance of peroxisome proliferator-activated receptors
Lancet, 354 (1999), pp. 141-148
11.
I. Issemann,S. Green
Activation of a member of the steroid hormone receptor superfamily by peroxisome proliferators
Nature (Lond), 347 (1990), pp. 645-650
12.
O. Braissant,F. Foufelle,C. Scotto,M. Dauca,W. Wahli
Differential expression of peroxisome proliferator-activated receptors (PPARs): tissue distribution of PPAR-alpha, -beta, and -gamma in the adult rat
Endocrinology, 137 (1996), pp. 354-366
13.
R.P. Brun,P. Tontonoz,B.M. Forman,R. Ellis,J. Chen,R.M. Evans
Differential activation of adipogenesis by multiple PPAR isoforms
Genes Dev, 10 (1996), pp. 974-984
14.
L. Michalik,W. Wahli
Peroxisome proliferator-activated receptors: three isotypes for a multitude of functions
Curr Opin Biotechnol, 10 (1999), pp. 564-570
15.
B. Staels,K. Schoonjans,J.C. Fruchart,J. Auwerx
The effects of fibrates and thiazolidinediones on plasma triglyceride metabolism are mediated by distinct peroxisome proliferator activated receptors (PPARs)
Biochimie, 79 (1997), pp. 95-99
16.
A. Schmidt,R.L. Vogel,K.M. Witherup,S.J. Rutledge,S.M. Pitzenberger,M. Adam
Identification of fatty acid methyl ester as naturally occurring transcriptional regulators of the members of the peroxisome proliferator-activated receptor family
Lipids, 31 (1996), pp. 1115-1124
17.
J. Berger,M.D. Leibowitz,T.W. Doebber,A. Elbrecht,B. Zhang,G. Zhou
Novel peroxisome proliferator-activated receptor (PPAR) gamma and PPARdelta ligands produce distinct biological effects
J Biol Chem, 274 (1999), pp. 6718-6725
15.
B.M. Forman,J. Chen,R.M. Evans
Hypolipidemic drugs, polyunsaturated fatty acids, and eicosanoids are ligands for peroxisome proliferator-activated receptors alpha and delta
Proc Natl Acad Sci USA, 94 (1997), pp. 4312-4317
16.
J. Berger,C. Biswas,N. Hayes,J. Ventre,M. Wu,T.W. Doebber
An antidiabetic thiazolidinedione potentiates insulin stimulation of glycogen synthase in rat adipose tissues
Endocrinology, 167 (1996), pp. 1984-1990
20.
S.A. Kliewer,K. Umesono,D.J. Noonan,R.A. Heyman,R.M. Evans
Convergence of 9-cis retinoic acid and peroxisome proliferator signalling pathways through heterodimer formation of their receptors
Nature (Lond), 358 (1992), pp. 771-774
21.
K. Schoonjans,G. Martin,B. Staels,J. Auwerx
Peroxisome proliferator-activated receptors, orphans with ligands and functions
Curr Opin Lipidol, 8 (1997), pp. 159-166
22.
M.E. Greene,B. Blumberg,O.W. McBride,H.F. Yi,K. Kronquist,K. Kwan
Isolation of the human peroxisome proliferator activated receptor gamma cDNA: expression in hematopoietic cells and chromosomal mapping
Gene Expr, 4 (1995), pp. 281-299
23.
A. Elbrecht,Y. Chen,C.A. Cullinan,N. Hayes,M. Leibowitz,D.E. Moller
Molecular cloning, expression and characterization of human peroxisome proliferator activated receptors gamma 1 and gamma 2
Biochem Biophys Res Commun, 224 (1996), pp. 431-437
24.
Y. Zhu,C. Qi,J.R. Korenberg,X.N. Chen,D. Noya,M.S. Rao
Structural organization of mouse peroxisome proliferator-activated receptor gamma (mPPAR gamma) gene: alternative promoter use and different splicingield two mPPAR gamma isoforms
Proc Natl Acad Sci USA, 92 (1995), pp. 7921-7925
25.
P. Tontonoz,E. Hu,R.A. Graves,A.I. Budavari,B.M. Spiegelman
mPPAR gamma 2: tissue-specific regulator of an adipocyte enhancer
Genes Dev, 8 (1994), pp. 1224-1234
26.
P. Tontonoz,E. Hu,BM. Spiegelman
Stimulation of adipogenesis in fibroblasts by PPAR gamma 2, a lipid- activated transcription factor
Cell, 79 (1994), pp. 1147-1156
27.
L. Fajas,J.C. Fruchart,J. Auwerx
PPAR gamma3 mRNA: a distinct PPARgamma mRNA subtype transcribed from an independent promoter
FEBS Lett, 438 (1998), pp. 55-60
28.
A. Vidal-Puig,M. Jimenez-Linan,B.B. Lowell,A. Hamann,E. Hu,B. Spiegelman
Regulation of PPAR gamma gene expression by nutrition and obesity in rodents
J Clin Invest, 97 (1996), pp. 2553-2561
29.
A.J. Vidal-Puig,R.V. Considine,M. Jimenez-Linan,A. Werman,W.J. Pories,J.F. Caro
Peroxisome proliferator-activated receptor gene expression in human tissues. Effects of obesity, weight loss, and regulation by insulin and glucocorticoids
J Clin Invest, 99 (1997), pp. 2416-2422
30.
A. Werman,A. Hollenberg,G. Solanes,C. Bjorbaek,A.J. Vidal-Puig,J.S. Flier
Ligand-independent activation domain in the N terminus of peroxisome proliferator-activated receptor gamma (PPARgamma). Differential activity of PPARgamma1 and -2 isoforms and influence of insulin
J Biol Chem, 272 (1997), pp. 20230-20235
31.
E. Hu,J.B. Kim,P. Sarraf,B.M. Spiegelman
Inhibition of adipogenesis through MAP kinase-mediated phosphorylation of PPARgamma
Science, 274 (1996), pp. 31771-31774
32.
B. Zhang,J. Berger,G. Zhou,A. Elbrecht,S. Biswas,S. White-Carrington
Insulin- and mitogen-activated protein kinase-mediated phosphorylation and activation of peroxisome proliferator-activated receptor gamma
J Biol Chem, 271 (1996), pp. 31771-31774
33.
P. Puigserver,Z. Wu,C.W. Park,R. Graves,M. Wright,B.M. Spiegelman
A cold-inducible coactivator of nuclear receptors linked to adaptive thermogenesis
Cell, 92 (1998), pp. 829-839
34.
B. Desvergne,W. Wahli
Peroxisome proliferator-activated receptors: nuclear control of metabolism
Endocr Rev, 20 (1999), pp. 649-688
35.
S.S. Deeb,L. Fajas,M. Nemoto,J. Pihlajamaki,L. Mykkanen,J. Kuusisto
A Pro12Ala substitution in PPARgamma2 associated with decreased receptor activity, lower body mass index and improved insulin sensitivity
Nat Genet, 20 (1998), pp. 284-287
36.
S.A. Kliewer,J.M. Lenhard,T.M. Willson,I. Patel,D.C. Morris,J.M. Lehmann
A prostaglandin J2 metabolite binds peroxisome proliferator-activated receptor gamma and promotes adipocyte differentiation
Cell, 83 (1995), pp. 813-819
37.
J. Berger,P. Bailey,C. Biswas,C.A. Cullinan,T.W. Doebber,N.S. Hayes
Thiazolidinediones produce a conformational change in peroxisomal proliferator-activated receptor-gamma: binding and activation correlate with antidiabetic actions in db/db mice
Endocrinology, 137 (1996), pp. 4189-4195
38.
B.M. Forman,P. Tontonoz,J. Chen,R.P. Brun,B.M. Spiegelman,R.M. Evans
15-Deoxy-delta 12, 14-prostaglandin J2 is a ligand for the adipocyte determination factor PPAR gamma
Cell, 83 (1995), pp. 803-812
39.
S.A. Kliewer,S.S. Sundseth,S.A. Jones,P.J. Brown,G.B. Wisely,C.S. Koble
Fatty acids and eicosanoids regulate gene expression through direct interactions with peroxisome proliferator-activated receptors alpha and gamma
Proc Natl Acad Sci USA, 94 (1997), pp. 4318-4323
40.
B.M. Spiegelman
PPAR-gamma: adipogenic regulator and thiazolidinedione receptor
Diabetes, 47 (1998), pp. 507-514
14.
A. Ibrahimi,L. Teboul,D. Gaillard,E.Z. Amri,G. Ailhaud,P. Young
Evidence for a common mechanism of action for fatty acids and thiazolidinedione antidiabetic agents on gene expression in preadipose cells
Mol Pharmacol, 46 (1994), pp. 1070-1076
42.
M. Adams,M.J. Reginato,D. Shao,M.A. Lazar,V.K. Chatterjee
Transcriptional activation by peroxisome proliferator-activated receptor gamma is inhibited by phosphorylation at a consensus mitogen- activated protein kinase site
J Biol Chem, 272 (1997), pp. 5128-5132
43.
I.B. Sears,M.A. MacGinnitie,L.G. Kovacs,R.A. Graves
Differentiation-dependent expression of the brown adipocyte uncoupling protein gene: regulation by peroxisome proliferator-activated receptor gamma
Mol Cell Biol, 16 (1996), pp. 3410-3419
44.
J.M. Gimble,G.M. Pighetti,M.R. Lerner,X. Wu,S.A. Lightfoot,D.J. Brackett
Expression of peroxisome proliferator activated receptor mRNA in normal and tumorigenic rodent mammary glands
Biochem Biophys Res Commun, 253 (1998), pp. 813-817
45.
E.D. Rosen,P. Sarraf,A.E. Troy,G. Bradwin,K. Moore,D.S. Milstone
PPAR gamma is required for the differentiation of adipose tissue in vivo and in vitro
Mol Cell, 4 (1999), pp. 611-617
46.
R.L. Rosenfield,A. Kentsis,D. Deplewski,N. Ciletti
Rat preputial sebocyte differentiation involves peroxisome proliferator- activated receptors
J Invest Dermatol, 112 (1999), pp. 226-232
47.
I.P. Tomlinson,W.F. Bodmer
Failure of programmed cell death and differentiation as causes of tumors: some simple mathematical models
Proc Natl Acad Sci USA, 92 (1995), pp. 11130-11134
48.
B.M. Spiegelman,J.S. Flier
Adipogenesis and obesity: rounding out the big picture
Cell, 87 (1996), pp. 377-389
49.
S. Altiok,M. Xu,B.M. Spiegelman
PPARgamma induces cell cycle withdrawal: inhibition of E2F/DP DNA- binding activity via down-regulation of PP2A
Genes Dev, 11 (1997), pp. 1987-1998
50.
E. Mueller,P. Sarraf,P. Tontonoz,R.M. Evans,K.J. Martin,M. Zhang
Terminal differentiation of human breast cancer through PPAR gamma
Mol Cell, 1 (1998), pp. 465-470
51.
P. Tontonoz,S. Singer,B.M. Forman,P. Sarraf,J.A. Fletcher,C.D. Fletcher
Terminal differentiation of human liposarcoma cells induced by ligands for peroxisome proliferator-activated receptor gamma and the retinoid X receptor
Proc Natl Acad Sci USA, 94 (1997), pp. 237-241
52.
E. Elstner,C. Muller,K. Koshizuka,E.A. Williamson,D. Park,H. Asou
Ligands for peroxisome proliferator-activated receptorgamma and retinoic acid receptor inhibit growth and induce apoptosis of human breast cancer cells in vitro and in BNX mice
Proc Natl Acad Sci USA, 95 (1998), pp. 8806-8811
53.
T. Kubota,K. Koshizuka,E.A. Williamson,H. Asou,J.W. Said,S. Holden
Ligand for peroxisome proliferator-activated receptor gamma (troglitazone) has potent antitumor effect against human prostate cancer both in vitro and in vivo
Cancer Res, 58 (1998), pp. 3344-3352
54.
E. Saáez,P. Tontonoz,M.C. Nelson,J.G. Álvarez,U.T. Ming,S.M. Baird
Activators of the nuclear receptor PPARgamma enhance colon polyp formation
Nat Med, 4 (1998), pp. 1058-1061
55.
A.M. Lefebvre,I. Chen,P. Desreumaux,J. Najib,J.C. Fruchart,K. Geboes
Activation of the peroxisome proliferator-activated receptor gamma promotes the development of colon tumors in C57BL/6J-APCMin/+ mice
Nat Med, 4 (1998), pp. 1053-1057
56.
P. Sarraf,E. Mueller,W.M. Smith,H.M. Wrigh,J.B. Kum,L.A. Aaltonen
Loss-of-function mutations in PPAR gamma associated with human colon cancer
Mol Cell, 3 (1999), pp. 799-804
57.
K. Iima,M. Yoshizumi,J. Ako,M. Eto,S. Kim,M. Hashimoto
Expression of peroxisome proliferator-activated receptor gamma (PPARgamma) in rat aortic smooth muscle cells
Biochem Biophys Res Commun, 247 (1998), pp. 353-356
58.
I. Inoue,K. Shino,S. Noji,T. Awata,S. Katayama
Expression of peroxisome proliferator-activated receptor alpha (PPAR alpha) in primary cultures of human vascular endothelial cells
Biochem Biophys Res Commun, 246 (1998), pp. 370-374
59.
L. Nagy,P. Tontonoz,J.G. Álvarez,H. Chen,R.M. Evans
Oxidized LDL regulates macrophage gene expression through ligand activation of PPARgamma
Cell, 93 (1998), pp. 229-240
60.
P. Tontonoz,L. Nagy,JG. Álvarez,VA. Thomazy,R.M. Evans
PPARgamma promotes monocyte/macrophage differentiation and uptake of oxidized LDL
Cell, 93 (1998), pp. 241-252
61.
G. Chinetti,S. Griglio,M. Antonucci,I.P. Torra,P. Delerive,Z. Majd
Activation of proliferator-activated receptors alpha and gamma induces apoptosis of human monocyte-derived macrophages
J Biol Chem, 273 (1998), pp. 25573-25580
62.
N. Marx,G. Sukhova,C. Murphy,P. Libby,J. Plutzky
Macrophages in human atheroma contain PPARgamma: differentiation- dependent peroxisomal proliferator-activated receptor gamma (PPARgamma) expression and reduction of MMP-9 activity through PPAR gamma activation in mononuclear phagocytes in vitro
Am J Pathol, 153 (1998), pp. 17-23
63.
M. Ricote,J. Huang,L. Fajas,A. Li,J. Welch,J. Najib
Expression of the peroxisome proliferator-activated receptor gamma (PPARgamma) in human atherosclerosis and regulation in macrophages by colony stimulating factors and oxidized low density lipoprotein
Proc Natl Acad Sci USA, 95 (1998), pp. 7614-7619
64.
R. Ross
The pathogenesis of atherosclerosis: a perspective for the 1990s
Nature (Lond), 362 (1993), pp. 801-809
65.
J.A. Berliner,M. Navab,A.M. Fogelman,J.S. Frank,L.L. Demer,P.A. Edwards
Atherosclerosis: basic mechanisms. Oxidation, inflammation, and genetics
Circulation, 91 (1995), pp. 2488-2496
66.
M. Ricote,A.C. Li,T.M. Willson,C.J. Kelly,C.K. Glass
The peroxisome proliferator-activated receptor-gamma is a negative regulator of macrophage activation
Nature (Lond), 161 (1998), pp. 978-984
67.
P.R. Colville-Nash,S.S. Qureshi,D. Willis,D.A. Willoughby
Inhibition of inducible nitric oxide synthase by peroxisome proliferator-activated receptor agonists: correlation with induction of heme oxygenase 1
J Immunol, 161 (1998), pp. 978-984
68.
Y. Hattori,S. Hattori,K. Kasai
Troglitazone upregulates nitric oxide synthesis in vascular smooth muscle cells
Hypertension, 33 (1999), pp. 943-948
69.
C. Jiang,A.T. Ting,B. Seed
PPAR-gamma agonists inhibit production of monocyte inflammatory cytokines
Nature (Lond), 391 (1998), pp. 82-86
70.
R.T. Lee,P. Libby
The unstable atheroma
Arterioscler Thromb Vasc Biol, 17 (1997), pp. 1859-1867
71.
TM. Willson,W. Wahli
Peroxisome proliferator-activated receptor agonists
Curr Opin Chem Biol, 1 (1997), pp. 235-241
72.
B. Staels,W. Koenig,A. Habib,R. Merval,M. Lebret,I.P. Torra
Activation of human aortic smooth-muscle cells is inhibited by PPARalpha but not by PPARgamma activators
Nature (Lond), 393 (1998), pp. 790-793
73.
H. Itoh,K. Doi,T. Tanaka,Y. Fukunaga,K. Hosoda,G. Inoue
Hypertension and insulin resistance: role of peroxisome proliferator- activated receptor gamma
Clin Exp Pharmacol Physiol, 26 (1999), pp. 558-560
74.
N. Marx,G.K. Sukhova,T. Collins,P. Libby,J. Plutzky
PPARalpha activators inhibit cytokine-induced vascular cell adhesion molecule-1 expression in human endothelial cells
Circulation, 99 (1999), pp. 3125-3131
75.
P. Delerive,F. Martin-Nizard,G. Chinetti,F. Trottein,J.C. Fruchart,J. Najib
Peroxisome proliferator-activated receptor activators inhibit thrombin- induced endothelin-1 production in human vascular endothelial cells by inhibiting the activator protein-1 signaling pathway
Circ Res, 85 (1999), pp. 394-402
76.
J. Plutzky
Atherosclerotic plaque rupture: emerging insights and opportunities
Am J Cardiol, 84 (1999), pp. 15-20
77.
I. Barroso,M. Gurnell,V.E. Crowley,M. Agostini,J.W. Schwabe,M.A. Soos
Dominant negative mutations in human PPARgamma associated with severe insulin resistance, diabetes mellitus and hypertension
Nature(Lond), 402 (1999), pp. 880-883
78.
M.F. Mitwally,N.K. Kuscu,T.M. Yalcinkaya
High ovulatory rates with use of troglitazone in clomiphene-resistant women with polycystic ovary syndrome
Hum Reprod, 14 (1999), pp. 2700-2703
79.
A. Vidal-Puig,M. Munoz-Torres,E. Jodar-Gimeno,C. Garcia-Calvente,P. Lardelli,M.E. Ruiz-Requena
Hyperinsulinemia in polycystic ovary syndrome: relationship to clinical and hormonal factors
Clin Investig, 72 (1994), pp. 853-857
80.
R.S. Legro,R. Spielman,M. Urbanek,D. Driscoll,J.F. Strauss,A. Dunaif
Phenotype and genotype in polycystic ovary syndrome
Recent Prog Horm Res, 53 (1998), pp. 217-256
81.
A. Dunaif
Insulin action in the polycystic ovary syndrome
Endocrinol Metab Clin North Am, 28 (1999), pp. 341-359
82.
C.B. Book,A. Dunaif
Selective insulin resistance in the polycystic ovary syndrome
J Clin Endocrinol Metab, 84 (1999), pp. 3110-3116
83.
J. Matsuda,K. Hosoda,H. Itoh,C. Son,K. Doi,I. Hanaoka
Increased adipose expression of the uncoupling protein-3 gene by thiazolidinediones in Wistar fatty rats and in cultured adipocytes
Diabetes, 47 (1998), pp. 1809-1814
84.
K. Murakami,K. Tobe,T. Ide,T. Mochizuki,M. Ohashi,Y. Akanuma
A novel insulin sensitizer acts as a coligand for peroxisome proliferator-activated receptor-alpha (PPAR-alpha) and PPAR-gamma: effect of PPARalpha activation on abnormal lipid metabolism in liver of Zucker fatty rats
Diabetes, 47 (1998), pp. 1841-1847
85.
A. Vella,P.C. De Groen,S.F. Dinneen
Fatal hepatotoxicity associated with troglitazone
Ann Intern Med, 129 (1998), pp. 1080
86.
P.B. Watkins,R.W. Whitcomb
Hepatic dysfunction associated with troglitazone
N Engl J Med, 338 (1998), pp. 916-917
87.
N. Gitlin,N.L. Julie,C.L. Spurr,K.N. Lim,H.M. Juarbe
Two cases of severe clinical and histologic hepatotoxicity associated with troglitazone
Ann Intern Med, 129 (1998), pp. 36-38
Correspondencia: Dr. A.J. Vidal Puig. Department of Medicine and Clinical Biochemistry. Box 232, level 4. Addenbrooke's Hospital. University of Cambridge. Cambridge CB2 2QR, UK.
Copyright © 2000. Elsevier España, S.L.